Based on the Galera Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Galera Therapeutics Inc is not available over the next 12 months. Galera Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Galera Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 8 negative signals. At the last closing, Galera Therapeutics Inc’s stock price was USD 0.05. Galera Therapeutics Inc’s stock price has changed by +5.62% over the past week, +51.61% over the past month and -73.89% over the last year.
No recent analyst target price found for Galera Therapeutics Inc
No recent average analyst rating found for Galera Therapeutics Inc
Company Overview Galera Therapeutics Inc
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania. Read Less
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for...Read More
Frequently Asked Questions About Galera Therapeutics Inc (GRTX) Stock
Stock Target Advisor's fundamental analysis for Galera Therapeutics Inc's stock is Very Bearish.
Unfortunately we do not have enough data on GRTX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on GRTX's stock to indicate what its average analyst target is.
GRTX stock's Price/Earning ratio is -99,999.99.
Our analysis grades GRTX stock's Price / Earning ratio at A+. This means that GRTX stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this GRTX may be undervalued for its sector.
The last closing price of GRTX's stock was USD 0.05.
The most recent market capitalization for GRTX is USD 1.47M.
Unfortunately we do not have enough analyst data on GRTX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Galera Therapeutics Inc's stock.
As per our most recent records Galera Therapeutics Inc has 7 Employees.
Galera Therapeutics Inc's registered address is P.O. Box 134, Malvern, PA, United States, 19355.
You can get more information about it from Galera Therapeutics Inc's website at https://www.galeratx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Galera Therapeutics Inc (GRTX) Stock
Stock Target Advisor's fundamental analysis for Galera Therapeutics Inc's stock is Very Bearish.
Unfortunately we do not have enough data on GRTX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on GRTX's stock to indicate what its average analyst target is.
GRTX stock's Price/Earning ratio is -99,999.99.
Our analysis grades GRTX stock's Price / Earning ratio at A+. This means that GRTX stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this GRTX may be undervalued for its sector.
The last closing price of GRTX's stock was USD 0.05.
The most recent market capitalization for GRTX is USD 1.47M.
Unfortunately we do not have enough analyst data on GRTX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Galera Therapeutics Inc's stock.
As per our most recent records Galera Therapeutics Inc has 7 Employees.
Galera Therapeutics Inc's registered address is P.O. Box 134, Malvern, PA, United States, 19355.
You can get more information about it from Galera Therapeutics Inc's website at https://www.galeratx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GRTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
